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Abstract
Background: Mesenchymal stem/stromal cells (MSCs) represent an attractive tool for cell-based cancer therapy mainly
because of their ability to migrate to tumors and to release bioactive molecules. However, the impact of MSCs on
tumor growth has not been fully established. We previously demonstrated that murine MSCs show a strong tropism
towards glioblastoma (GBM) brain xenografts and that these cells are able to uptake and release the chemotherapeutic
drug paclitaxel (PTX), maintaining their tropism towards the tumor. Here, we address the therapy-relevant
issue of using MSCs from human donors (hMSCs) for local or systemic administration in orthotopic GBM
models, including xenografts of patient-derived glioma stem cells (GSCs).
Methods: U87MG or GSC1 cells expressing the green fluorescent protein (GFP) were grafted onto the striatum of
immunosuppressed rats. Adipose hMSCs (Ad-hMSCs), fluorescently labeled with the mCherry protein, were inoculated
adjacent to or into the tumor. In rats bearing U87MG xenografts, systemic injections of Ad-hMSCs or bone
marrow (BM)-hMSCs were done via the femoral vein or carotid artery. In each experiment, either PTX-loaded or unloaded
hMSCs were used. To characterize the effects of hMSCs on tumor growth, we analyzed survival, tumor volume, tumor cell
proliferation, and microvascular density.
Results: Overall, the AD-hMSCs showed remarkable tropism towards the tumor. Intracerebral injection of Ad-hMSCs
significantly improved the survival of rats with U87MG xenografts. This effect was associated with a reduction in tumor
growth, tumor cell proliferation, and microvascular density. In GSC1 xenografts, intratumoral injection of
Ad-hMSCs depleted the tumor cell population and induced migration of resident microglial cells. Overall,
PTX loading did not significantly enhance the antitumor potential of hMSCs. Systemically injected Ad- and
BM-hMSCs homed to tumor xenografts. The efficiency of hMSC homing ranged between 0.02 and 0.5% of
the injected cells, depending both on the route of cell injection and on the source from which the hMSCs
were derived. Importantly, systemically injected PTX-loaded hMSCs that homed to the xenograft induced
cytotoxic damage to the surrounding tumor cells.
Conclusions: hMSCs have a therapeutic potential in GBM brain xenografts which is also expressed against
the GSC population. In this context, PTX loading of hMSCs seems to play a minor role.
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Background
Mesenchymal stem/stromal cells (MSCs) were first
defined by Friedenstein et al. [1] as bone marrow
(BM)-derived, adherent, fibroblast-shaped cells with
the capacity to differentiate into bone. These cells were
later demonstrated to have the ability to self-renew, form
colonies, and differentiate toward different mesodermal
cell types [2]. Three minimal criteria have been established
to define MSCs: 1) to adhere to plastic in vitro; 2) to
exhibit a set combination of surface markers (CD73+,
CD90+, CD105+, CD44+, CD166+, CD34–, CD31–, CD40–,
CD45–, CD14–, and HLA-II–); and 3) to differentiate in
vitro into osteoblasts, chondrocytes, and adipocytes [3].
Beside these minimal standards, further criteria for MSC
identification may vary, making it difficult to strictly define
MSCs. MSC populations with similar multilineage differ-
entiation potentials in vitro can be obtained from many
non-BM tissues, including the adipose tissue [4], placenta
[5], umbilical cord, and peripheral blood [6], and even
from gingival tissue [7]. In the last decade, MSCs held
great promise for cell-based therapy in several disorders,
including immune disorders and tumors, due to their
ability to home to damaged tissues, to release bioactive
molecules, and to have immunomodulatory actions.
Moreover, MSCs have been shown to cross the blood-
brain barrier (BBB), a characteristic that represents an
important aspect when considering MSCs as a thera-
peutic option for brain tumors. Although the mecha-
nisms driving MSCs to their cellular targets are still
widely unknown, the therapeutic use of MSCs has been
studied in an impressive number of clinical trials [8].
However, the issue of whether the presence of MSCs in
the tumor microenvironment and the molecular crosstalk
with the resident cells may result in tumor-suppressive
effects or, alternatively, may favor tumor growth is still
unclear. Several hypotheses have been postulated to
explain the antitumor effects of MSCs, including inhib-
ition of proliferation-related signaling pathways, such as
AKT, PI3K, and Wnt, inhibition of cell-cycle progression,
downregulation of XIAP (X-linked inhibitor of apoptosis
protein), and suppression of angiogenesis [9–16].
Using an orthotopic glioblastoma (GBM) model, we
recently demonstrated that murine MSCs have a
strong tropism towards tumor cells and, when loaded
with paclitaxel (PTX), induce cytotoxic damage in the
tumor cells [17]. In the present work, we addressed
some therapy-relevant issues for using human MSCs
(hMSCs) in GBM, that included: 1) the ability of intra-
cerebrally injected hMSCs, either loaded with PTX or
unloaded, to affect tumor growth and survival; 2) whether
a hMSC-based therapy may be effective against the cancer
stem cell population of GBM; and 3) the efficiency of
systemically injected hMSCs to home to GBM brain
xenografts.
Methods
Cell cultures
Tumor cells
All cells were cultured at 37 °C in a humidified atmosphere
containing 5% carbon dioxide. U87MG GBM cells (HTB14;
ATCC) were cultured in high-glucose Dulbecco’s modified
Eagle’s medium (DMEM; Sigma, St. Louis, MO, USA)
supplemented with 10% fetal bovine serum (FBS; Gibco,
Life Technologies, Waltham, MA, USA) under standard
conditions. The patient-derived glioma stem-like cell
(GSC) line GSC1 that had been established in our
laboratory and extensively studied in brain xenografts
[18] was cultured in a serum-free medium supplemented
with epidermal growth factor (EGF) and basic fibroblast
growth factor (bFGF) as described previously [19].
Human adipose-derived and bone marrow-derived
mesenchymal stromal cells (Ad-hMSCs and BM-hMSCs)
According to the policies approved by the Institutional
Review Boards for Human Studies local ethical committees
(IRB 48/2013, Istituto Neurologico Carlo Besta), adipose
tissue samples were obtained after informed consent. Two
Ad-hMSC cultures, here named Ad09 and AdFV, were
established from a male (34 years old) and a female
(64 years old) donor, respectively. The Ad-hMSCs were
isolated following a previously described procedure [20, 21].
Briefly, 5 ml sterile peri-umbilical fat lipo-aspirates for
each sample were processed. Lipoaspirates were repeatedly
washed with phosphate-buffered saline (PBS) for removal
of residual blood at 250 × g. After the liquid phase removal,
collagenase solution (0.25% w/v; Sigma) plus 200 μl DNAse
(Sigma) at 1:100 dilution were added. After enzymatic di-
gestion overnight at 37 °C, cells were washed by centrifuga-
tion at 250 × g for 10 min. The pellets were resuspended in
Iscove’s modified Dulbecco’s medium (IMDM) + 5% FBS
(Gibco, Life Technologies, Monza, Italy), seeded into T25
culture flasks, and incubated at 37 °C in a humidified at-
mosphere containing 5% CO2. The following day, the
medium was aspirated and replaced with IMDM+ 5% FBS
and 50 ng/ml bFGF (Lonza, Walkersville, MD. USA). After
5–7 days of culture, the plastic adherent cells were har-
vested with trypsin and processed for the removal of CD31
+ cells using magnetic beads (Invitrogen, Italy, CELLection™
Pan Mouse IgG Kit) as previously described [22]. The
remaining CD31– cells, i.e., Ad-hMSCs, were expanded in
IMDM + 5% FBS + bFGF and routinely passaged to 70–
80% confluence. To confirm their mesenchymal pheno-
type, Ad-hMSC cultures were characterized by flow cy-
tometry. Briefly, after trypsinization, cells were
resuspended in PBS at a concentration of 1 × 105/100 μl
and incubated with 10 μl conjugated primary antibody for
30 min at 4 °C in the dark. Phycoerythrin (PE) conjugate-
antibodies were used: anti-human CD90PE (Millipore, Bil-
lerica, MA, USA; working dilution 1:10), anti-human
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CD105PE, anti-human CD73PE, and anti-human CD44PE
(BD Pharmingen San Jose, CA, USA; working dilution
1:10). Aspecific staining was determined with the appro-
priate isotype control. At least 20,000 events were ac-
quired for each sample on a FACS Advantage SE (BD
Bioscience, San Diego, CA, USA) flow cytometer and
the acquisition analyses were performed using Cell-
Quest software (BD Bioscience). Ad-hMSCs were tested
for their capacity to differentiate into osteocytes, chondro-
cytes, and adipocytes according to the methods suggested
by Pittenger et al. [2]. Cells were plated into 35-mm Petri
dishes at a density of 10,000 cells/cm2 in 1 ml of culture
medium per Petri dish which was replaced with specific dif-
ferentiation medium after 72 h. For osteogenic differenti-
ation, cells were cultured in DMEM/F12 + 10% FBS
supplemented with 10 nM dexamethasone, 10 mM gly-
cerol-2-phospate, and 0.3 mM L-ascorbic acid (Sigma-Al-
drich). After 14 days, culture monolayers were fixed in
cooled methanol and then processed for alkaline phos-
phatase staining. For chondrocytic differentiation, cells
were cultured in hMSC chondrogenesis induction medium
(Provitro, Germany) according to the micro-mass method
[23] with some modifications, as reported by Pessina et al.
[24]. To induce adipocytic differentiation, cells were cul-
tured in DMEM high glucose + 10% FBS supplemented
with 200 μM indomethacin (Alexis Biochemicals, USA),
0.5 mM isobutylmethylxanthine, 1 μM dexamethasone,
1 μM hydrocortisone, and 10 mg/l insulin (all from Sigma-
Aldrich). After 10 days of culture, cells were fixed with 4%
formalin solution and then processed for Oil red O staining
(Sigma-Aldrich). BM-hMSCs were purchased from Lonza
(Walkersville, MD, USA) and cultured according to the
manufacturer’s instructions. Table 1 summarizes the
characterization of Ad09-, AdFV-, and BM-hMSC lines.
Production of viral stocks and cell infections
All fluorescent cell strains used in our experiments were
obtained by lentiviral stable transduction of either green
fluorescent protein (GFP) or mCherry protein, as de-
scribed in [25]. Briefly, viral particles were produced
in HEK 293 T cells by transient transfection using
Lipofectamine reagent (Life Technologies, Waltham,
MA, USA). HEK 293 T cells were co-transfected with
the lentiviral constructs pCLLsin.PPT.hPGK.GFP.pre
[25] or pLVXmCherry-C1 (Clonetech Laboratories
Inc., MountainView, CA, USA), together with the
packaging plasmids pMDL, pRSV, and VSVG. Super-
natants were collected every 24 h between 48 and 72 h
after transfection and used in three successive rounds
of infection in the presence of 8 μg/ml polybrene. Lentiviral
infection occurred with high efficiency, as assessed by green
or red fluorescence, so that no enrichment for transduced
cells was required.
Loading of Ad-hMSCs with PTX
GFP-MSCs were loaded with 2000 ng/ml PTX (2340 nM)
(Adipogen, Liestal, Switzerland), as described in Pessina et
al. [26]. Briefly, cells were incubated with PTX for 24 h. At
the end of incubation, cells were trypsinized, extensively
washed with HBSS, and seeded in a new flask. After 24 h,
conditioned medium (CM) was collected and used to cul-
ture U87MG. Parallel cultures of U87MG cells were grown
with CM from unloaded MSCs and used as controls.
MTS assay
The effect of CM from PTX-hMSCs was evaluated both
on U87MG and on GSC cell viability by Cell Titer 96
Aqueous One Solution Cell Proliferation Assay (Promega,
Madison, WI, USA). Cells were seeded on a 96-well plate
and cultured for 5 days in the presence of serial 1:2
dilutions of CM from PTX-loaded or unloaded Ad-
hMSCs, or serial 1:2 dilutions of PTX (initial concen-
tration 100 ng/ml). Cell viability was calculated as the
ratio between the absorbance of treated and control
(sham-treated) tumor cells. Mean values and standard
deviation were generated from two biological repli-
cates. Each experiment was performed at least three
times. Representative results of a single experiment
are shown in Additional file 1: Figure S1. Three inde-
pendent experiments were consistent.
Cocultures
Coculture experiments were performed by plating
GFP-labeled tumor cells (U87MG or GSCs) mixed
with Cherry-labeled Ad-hMSCs at a 3:1 ratio on glass
slides. We performed the experiment using either
PTX-loaded or unloaded Ad-hMSCs. Twenty-four or
48 h later, cells were fixed in 4% paraformaldehyde for
20 min at room temperature. Fixation was quenched
Table 1 Phenotypic characterization of hMSCs
Phenotypic markers Ad-09 Ad-FV BM
CD90 + + +
CD105 + + +
CD73 + + +
CD44 + + +
CD166 + + +
CD31 – – Not tested
CD40 – – Not tested
CD45 – – –
CD34 – – –
HLA II – – –
CD14 Not tested Not tested –
CD19 Not tested Not tested –
BM bone marrow, hMSC human mesenchymal stem/stromal cell
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by washing twice with PBS. Cells were permeabilized
with PBS containing 0.3% Triton X-100 for 20 min at
room temperature in a humid chamber, and then incu-
bated in 4′,6-diamidino-2-phenylindole (DAPI; 1:4000) for
10 min and washed before mounting the coverslips with
mounting medium. The cytotoxic effect induced by PTX
release was evaluated by counting the tumor cells with
aberrant spindles and the multinucleated tumor cells.
Orthotopic xenografting of U87MG cells and patient-
derived GSC1
Orthotopic xenograft models of human GBM cells were
developed in immunosuppressed adult rats (males;
200–250 g). Either athymic nude rats (Charles River,
Milan, Italy) or cyclosporine immunosuppressed rats
(Wistar, Università Cattolica Breeding Laboratory, Rome,
Italy) were used.
For cyclosporine immunosuppression, the rats were
treated with subcutaneous injections of cyclosporine
(30 mg/kg, three times per week) beginning 7 days
before tumor implantation. For brain grafting, the rats
were anesthetized with an intraperitoneal injection of
diazepam (2 mg/100 g) followed by intramuscular injec-
tion of ketamine (4 mg/100 g). Animal skulls were immo-
bilized in a stereotactic head frame. A burr hole was made
1 mm anterior to the bregma and 4 mm right of the mid-
line. The tip of a 10-μl Hamilton microsyringe was placed
at a depth of 5 mm from the dura and 3 × 105 of either
GFP-labeled U87MG or GSC1 were injected over 10 min.
In the U87MG xenografts, either PTX-loaded or
unloaded hMSCs were injected immediately after tumor
cell implantation through a second hole that was made
1 mm anterior to the bregma and 2 mm right of the
midline. Fluorescently labeled Ad-hMSCs (105 cells)
were injected at 5 mm depth from the dura. In the
GSC1 xenografts, injection of Ad-hMSCs (either PTX-
loaded or unloaded) was made 16 weeks after tumor cell
implantation to the same stereotactic coordinates as
used for tumor grafting. Control rats were grafted with
3 × 105 of either GFP-U87MG or GFP-GSC1 cells or saline.
After surgery, the animals were kept under pathogen-free
conditions in positive-pressure cabinets (Tecniplast
Gazzada, Varese, Italy) and observed daily for neuro-
logical signs and body weight loss.
Systemic injection of hMSCs
Systemic injection of either Ad- or BM-hMSCs was
performed in athymic rats bearing U87MG xenografts by
2 weeks after U87MG cell implantation. Three routes of
systemic injection of hMSCs were used: the femoral vein,
the common carotid artery, and the common carotid
artery after ligation of the external carotid artery. Each
animal received 2 × 105 fluorescent hMSCs resuspended
in 300 μl saline that were slowly injected over 10 min.
Fluorescence microscopy and immunofluorescence of
brain tumor xenografts
Rats grafted with U87MG and GSC1 cells were sacrificed
1 week and 3 weeks after intracerebral hMSC injections,
respectively. Rats receiving systemic hMSCs were allowed
to survive from 1 to 72 h after injection.
The rats were deeply anesthetized and transcardially
perfused with 0.1 M PBS (pH 7.4), followed by 4% para-
formaldehyde in 0.1 M PBS. The brains were removed,
post-fixed in 4% paraformaldehyde in PBS for 3 days,
and cryoprotected in PBS with 30% sucrose for 3 days.
Coronal sections of the brain (40-μm thick) were blocked
in PBS with 10% bovine serum albumin (BSA) and 0.3%
Triton X-100 for 45 min. Sections were incubated over-
night at 4 °C with primary antibodies in PBS with 0.3%
Triton X-100 and 0.1% normal donkey serum (NDS).
Monoclonal antibodies used were: anti-rabbit Ki-67
(1:150; Thermo Fisher Scientific, Waltham, MA, USA)
and mouse anti-Rat Blood-Brain Barrier (Clone SMI-71)
(1:500; Biolegend, San Diego, CA, USA). Polyclonal anti-
bodies used were: rabbit anti-Iba1 (1:200; Wako Chemi-
cals, Richmond, VA, USA), goat anti-CD34 (C-18) (1:50;
Santa Cruz Biotechnology, Dallas, TX, USA), rat anti-
mouse CD31 (1:100; BD Bioscience, Franklin Lakes, NJ,
USA), and rabbit anti-GFAP (1:1000; Dako Italia, Milan,
Italy). For detecting brain microvessels, sections were in-
cubated overnight at 4 °C in PBS with 0.3% Triton X-100
and 0.1% NDS with lectin from Lycopersicon esculentum
(tomato) biotin conjugate (1:500; Sigma-Aldrich, St. Louis,
MO, USA) together with primary antibodies. Slices were
rinsed and incubated in PBS containing 0.3% Triton
X-100 with secondary antibodies for 2 h at room
temperature. Secondary antibodies used were: Alexa
Fluor 647 or 555 or 488 donkey anti-mouse, Alexa
Fluor 488 or 555 or 647, donkey anti-rabbit secondary
antibodies (1:500; Thermo Fisher Scientific, Waltham,
MA, USA), Alexa Fluor 488 or 555 donkey anti-goat
antibodies (1:400; Thermo Fisher Scientific, Waltham,
MA, USA), and Cy3 donkey anti-Rat (1:200; EMD
Millipore, Billerica, MA, USA).
For lectin immunostaining, sections were incubated
for 2 h at room temperature in PBS containing 0.3%
Triton X-100 with streptavidin protein, DyLight 405
conjugate, or streptavidin Alexa Fluor® 647 conjugate
(1:200; Thermo Fisher Scientific, Waltham, MA, USA).
Before mounting, slices were incubated with DAPI (1:4000;
Sigma-Aldrich) for 10 min. Immunofluorescence was ob-
served with a laser confocal microscope (SP5; Leica) and
images were acquired. Image analysis was performed with
Leica Application Suite X software.
Tumor volume calculation
For each brain, serial thick sections (40 μm) starting
from the olfactory bulb to the cerebellum were prepared.
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Slices were collected in a 24 multiwell plate. Every brain
slice was consecutively placed in a well starting with well
1 and ending with well 24. This procedure was repeated
until the whole brain was cut. For brain tumor volume
calculation, the brain slices of one tube were transferred
to a new well and incubated for 20 min in PBS containing
0.3% Triton X-100 with DAPI (1:4000; Sigma-Aldrich).
Fluorescent tumor area of every slice was observed and
acquired with a laser confocal microscope (SP5; Leica).
Images were computer processed in ImageJ (National
Institutes of Health) in order to determine the tumor
areas of each slice in a well. The following formula was
used to calculate brain tumor volume: tumor volume =
slice size (40 μm) × step size between the slices (24) ×
sum of tumor areas from one well. The tumor volume
for each brain was calculated by analyzing slices from
at least two wells.
Assessment of microvascular density
For angiogenesis quantification we determined the density
of tumor vessels stained by immunoreaction with the anti-
CD34 antibody. We acquired at least 20 no-overlapping
images (20× magnification) of each tumor. Microvascular
density was assessed by evaluating the fraction of tumor
area occupied by CD34-positive endothelial cells per micro-
scope field using NIH ImageJ software for image processing
(https://imagej.nih.gov/ij/).
Statistical analysis
Results are presented as mean ± standard error of the
mean (SEM) and statistically evaluated by a two-tailed
Student’s t test. Data from cocultures are evaluated by
one-way analysis of variance (ANOVA). Multiple com-
parisons were performed using the post-hoc Bonferroni
comparison test. Survival curves were plotted using the
Kaplan-Meier method and differences between groups
were evaluated using the log-rank test. Statistical sig-
nificance was assigned to p values <0.05. All statistical
analyses were performed with GraphPad Prism 5 software
(GraphPad Software, San Diego, CA, USA).
Results
Intracerebral injections of Ad-hMSCs in U87MG orthotopic
xenografts
In a previous study, we showed that murine PTX-loaded
MSCs injected adjacently to U87MG brain xenografts
are able to migrate towards the tumor and to induce
PTX-specific cytotoxic damage in the tumor cells [17].
The present experiment was designed to investigate
whether Ad-hMSCs may exert an antitumor effect com-
parable to that of murine MSCs, and if such an effect
may be relevant to animal survival. Both unloaded and
PTX-loaded Ad-hMSCs were assessed for their ability to
migrate towards the tumor and to exert antiproliferative
effects. To preliminary characterize in vitro the efficiency
of PTX loading/releasing by Ad-hMSCs, we followed our
standardized procedure [26]. The ability of CM from
PTX-loaded Ad-hMSCs to affect U87MG cell viability was
addressed by MTS assay, in comparison with U87MG
cells treated with scaled doses of PTX. CM from unloaded
Ad-hMSCs was used as the negative control. Ad-hMSCs
showed an uptake/release capacity comparable to that of
murine MSCs [17, 26] (Additional file 1: Figure S1). More-
over, we cocultured U87MG cells either with PTX-loaded
or with unloaded Ad-hMSCs at a 3:1 ratio. After 24 or
48 h, cells were fixed and analyzed with respect to their
spindle morphology and nuclear content (Additional
file 2: Figure S2a). At 24 h of coculturing, the percent-
age of U87MG with mono/multipolar spindles was
significantly higher in cocultures with PTX-Ad-hMSCs
as compared to U87MG cocultured with unloaded Ad-
hMSCs (Additional file 2: Figure S2b) or to single U87MG
cell cultures (data not shown). At 48 h of coculturing, we
observed an impressive increase in multinucleated
U87MG tumor cells in coculture with PTX-Ad-hMSCs as
compared to U87MG cells cocultured with unloaded Ad-
hMSCs (Additional file 2: Figure S2c) or to single popula-
tions of control U87MG (data not shown).
Cyclosporine immunosuppressed rats were stereotac-
tically grafted into the right striatum with GFP-labeled
U87MG cells. In the same procedure, mCherry-labeled
Ad09-hMSCs were injected adjacent to U87MG cells
(Fig. 1a). Either PTX-loaded or unloaded Ad-hMSCs
were injected in separate groups of rats. One week after
grafting, the vast majority of Ad-hMSCs had migrated
from the grafting site towards the tumor cells (Fig. 1b).
Migration of U87MG cells towards the site of Ad-hMSC
injection was also noted; however, this involved only rare
tumor cells. Migrating Ad-hMSCs populated all regions
of the tumor xenograft without any specific tropism,
such as, for example, for the vascular structures. There
were no differences in the pattern of migration through
the brain parenchyma between PTX-loaded and unloaded
Ad-hMSCs. Importantly, the U87MG cells that surrounded
PTX-loaded Ad-hMSCs showed the typical cytotoxic
effects produced by PTX, such as aberrant mitoses with
multipolar spindles, eventually resulting in multinucle-
ated tumor cells (Fig. 1c). By analyzing the area within
a radius of 50 μm from each Ad-hMSC, we found that
the percentage of multinucleated cells was 21.68 ±
2.22% (mean ± SEM) and 4.27 ± 1.03% in the U87MG
xenografts injected with PTX-loaded Ad-hMSCs and
unloaded Ad-hMSCs, respectively (p < 0.0001 by Student’s
t test) (Fig. 1d). At distances further than 50 μm from any
single Ad-hMSC, the fraction of multinucleated U87MG
cells dropped massively.
To assess whether intracerebral Ad-hMSC injections
may have any effect on survival, we grafted the GFP-labeled
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U87MG cells onto the striatum of immunosuppressed rats
and treated the rats with a single intracerebral injection of
either mCherry Ad-hMSCs (n = 4) or PTX-loaded mCherry
Ad-hMSCs (n = 5), or saline (n = 4). The animals were
sacrificed after the appearance of neurological deficits or by
losing >20% of their body weight. Kaplan-Meier analysis
showed that rats injected with Ad-hMSCs survived signifi-
cantly longer than controls (Fig. 1e). Although the median
survival was better in rats treated with PTX-loaded Ad-
hMSCs, there was no significant difference in survival
between the animals injected with PTX-loaded Ad-hMSCs
and those injected with unloaded Ad-hMSCs (median
survival 24 and 21 days in PTX-loaded and unloaded Ad-
hMSCs, respectively; p = 0.2404 by Student’s t test). In
order to relate survival to tumor growth and pathology, a
subset of rats was sacrificed at 2 weeks after grafting and
the brain was assessed for tumor volume, tumor cell prolif-
eration, and microvascular density (Fig. 1f–i). Both rats
treated with unloaded Ad-hMSCs (n = 3) and those treated
with PTX-loaded Ad-hMSCs (n = 3) harbored significantly
smaller brain tumors than saline-treated controls (n = 3)
(Fig. 1f). The Ki-67 labeling index was significantly reduced
both in tumors treated with unloaded Ad-hMSCs and in
those treated with PTX-loaded Ad-hMSCs (Fig. 1g). Cell
proliferation was 82.04 ± 4.48% (mean ± SEM), 37.00 ±
2.06%, and 46.05 ± 2.97% in xenografts injected with
U87MG cells plus saline, or with U87MG plus unloaded
Ad-hMSCs, or with U87MG plus PTX-loaded Ad-
hMSCs, respectively (p < 0.0001 both for U87MG vs
U87MG plus hMSCs and for U87MG vs U87MG plus
PTX-loaded hMSCs by Student’s t test).
The microvascular density was significantly reduced
compared with saline-injected controls for both the
U87MG xenografts treated with unloaded and in those
treated with PTX-loaded Ad-hMSCs. Microvascular
density scored 10.27 ± 0.59 (mean ± SEM), 2.98 ± 0.26,
and 2.48 ± 0.32 in control U87MG, U87MG plus Ad-
hMSCs, and U87MG plus PTX-loaded Ad-hMSCs,
respectively (p < 0.0001 by Student’s t test).
Overall, these experiments demonstrated that intracere-
bral injections of Ad-hMSCs have a therapeutic potential
in U87MG brain xenografts by prolonging animal survival.
This potential is related to inhibited tumor growth due to
decreased cell proliferation and tumor angiogenesis. In
this context, PTX loading of Ad-hMSCs seems to play a
minor role. Although injection of PTX Ad- hMSCs
yielded the best results in terms of survival and PTX-
induced damage could be detected in the tumor cells,
PTX did not add significant advantages to the inhibition
of tumor growth, cell proliferation, or angiogenesis by the
Ad-hMSCs.
Intratumoral injections of Ad-hMSCs in established orthotopic
xenografts of patient-derived GSCs
GSCs have been shown to generate tumor xenografts
that reproduce the parent tumor more closely than serum-
cultured GBM cell lines, such as the U87MG cells [19].
Furthermore, GSCs are highly resistant to anticancer drugs
[27, 28] and are believed to be responsible for tumor recur-
rence after surgery and radiochemotherapy. From a transla-
tional point of view, it is important to know whether locally
applied hMSCs may be effective against GSCs; for example,
to sterilize the tumor bed after surgical resection. We
aimed to investigate the therapeutic potential of intra-
tumoral hMSC injections in established brain xeno-
grafts of patient-derived GSCs. To preliminary test the
effects exerted on GSCs by exposure to Ad-hMSCs, we
applied the same approach used for U87MG. We either
exposed GSCs to the CM from PTX-loaded or unloaded
Ad-hMSCs or, alternatively, we cocultured GSCs with
PTX-loaded or unloaded Ad-hMSCs (3:1 ratio). As ex-
pected, PTX cytotoxicity was lower than that observed on
U87MG cells. However, CM from PTX-loaded Ad-
hMSCs was able to induce a cytotoxic effect on GSCs
as well (Additional file 1: Figure S1). Moreover, when
we cocultured GSCs with PTX-Ad-hMSCs for 24 h
(Additional file 2: Figure S2a) we found that the aber-
rant spindles were significantly increased in the tumor
(See figure on previous page.)
Fig. 1 Intracerebral injections of hMSCs in U87MG orthotopic xenografts. a Schematic drawing of the intracerebral injection of m-Cherry adipose-derived
human mesenchymal stem/stromal cells (Ad-hMSCs) (red) and green fluorescent protein (GFP) U87MG cells (green) in cyclosporine immunosuppressed rats.
b Microphotographs on fluorescence microscopy of a coronal section of rat brain showing the injection sites at low (left panel; scale bar= 500 μm) and
higher (right panel; scale bars= 250 μm) magnification. At 1 week after grafting, the vast majority of the Ad-hMSCs had migrated towards the tumor. c
Microphotograph of the tumor epicentre showing Ad-hMSCs that have migrated into the tumor (left panel; scale bar = 40 μm). Detail of a
paclitaxel (PTX)-loaded Ad-hMSC lying adjacent to a multinucleated U87MG tumor cell (yellow arrow; scale bar = 25 μm). d Bar graph showing the
percentage of multinucleated U87MG cells in brain xenografts injected with PTX-loaded Ad-hMSCs and in those injected with unloaded Ad-hMSCs
(***p < 0.0001). e Kaplan-Meier curves for the survival of rats grafted with U87MG cells (red line), U87MG cells plus Ad-hMSCs (green line), and U87MG
cells plus PTX-loaded Ad-hMSCs (blue line). f Bar graph showing the volume of U87MG xenografts in control rats and in rats treated with unloaded
Ad-hMSCs and in those treated with PTX-loaded Ad-hMSCs (*p < 0.05). g Bar graph showing cell proliferation, as assessed by Ki67 labeling, in control
U87MG xenografts and in those injected with unloaded Ad-hMSCs or with PTX-loaded Ad-hMSCs (***p < 0.0001). h Assessment of microvascular
density. Sections of the brain xenograft immunostained with anti-CD34 were acquired, converted into grayscale, and assessed by computerized image
analysis. Scale bar = 100 μm. i Bar graph showing microvascular density in control U87MG xenografts and in xenografts injected with unloaded
Ad-hMSCs or with PTX-loaded Ad-hMSCs. Values on the y axis represent the percent of the endothelial area (CD34+)/tumor area (EA/tumor
area) per microscope field (***p < 0.0001). CNTR control
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cell nuclei (Additional file 2: Figure S2b). After 48 h, there
was a significant increase in multinucleated GSCs in cocul-
tures with PTX-Ad-hMSCs (Additional file 2: Figure S2c).
No significant difference was observed in control cocultures
(GSCs/Ad-MSCs) (Additional file 2: Figure S2c) or in single
GSC cell cultures (data not shown).
GFP-expressing GSC1 cells were grafted onto the
striatum of athymic rats (n = 11). Sixteen weeks later,
mCherry-Ad-hMSCs were injected intracerebrally at
the same stereotactic coordinates used for tumor cell
grafting (Fig. 2a). For this series of experiments, we
used the mCherry FVAd-hMSCs, which were injected
either loaded with PTX (n = 4 rats) or unloaded (n = 4
rats) (Additional file 1: Figure S1). Three weeks after
the injection of Ad-hMSCs, these cells were found to
populate the tumor core (Fig. 2b). Interestingly, the
density of GSC1 cells in areas injected with Ad-hMSCs
was much lower than in the injected regions of saline-
treated xenografts (n = 3 rats). In regions injected with
Ad-hMSCs, immunostaining with anti-Iba1 showed a
strong microglial activation that was associated with
depletion of tumor cells, suggesting an inflammatory
reaction with phagocytic activity (Fig. 2c). Overall, the
tumor regions injected with Ad-hMSCs showed GSC
density of 5.64 ± 1.94 (mean ± SEM) cells/100 μm2,
whereas GSC density in saline-injected regions of control
xenografts was 49.9 ± 1.91 cells/100 μm2 (p < 0.0001 by
Student’s t test) (Fig. 2d). There were no differences in
GSC density between tumor regions injected with PTX-
loaded Ad-MSCs and those injected with unloaded Ad-
hMSCs. However, engraftment of PTX-loaded Ad-hMSCs
resulted in multinucleated tumor cells (Fig. 2e and f). As
compared with saline-injected controls, proliferation of
GSCs was significantly reduced both in xenografts injected
with unloaded Ad-hMSCs and in those injected with
PTX-loaded Ad-hMSCs (Fig. 2g–i). The Ki-67 labeling
index was 14.35 ± 2.67% (mean ± SEM), 10.75 ± 1.25%,
and 23.5 ± 2.38% in xenografts injected with Ad-hMSCs,
PTX-loaded Ad-hMSCs, and saline, respectively (Ad-
hMSCs vs control, p = 0.0437; PTX-loaded Ad-hMSCs
vs control, p = 0.0068; Ad-hMSCs vs PTX-loaded Ad-
hMSCs, p = not significant; all by Student’s t test).
Together, the experiments on intracerebral injection of
Ad-hMSCs demonstrated that local therapy with hMSCs
may be an effective strategy not only against the bulk of
GBM, modeled by the U87MG cell xenografts, but also
against GSCs, which represents the subpopulation of tumor
cells responsible for resistance to radiochemotherapy and
recurrence.
Systemic injection of hMSCs in established orthotopic
xenografts of U87MG cells
On a translational basis, direct injection of hMSCs into
the brain parenchyma may reasonably be proposed at
primary surgery to sterilize the resection cavity, but it is
challenging in cases of tumor recurrence after standard
radiochemotherapy due to the iatrogenic risks of multiple
intracerebral injections along the paths of the recurrent
tumor. With regard to a less invasive approach to tumor
recurrences, we investigated the ability of systemically
injected hMSCs to home to the parenchyma of GBM
through the tumor vasculature and the potential of these
cells to exert any anticancer activity per se or after PTX
loading. We first established brain tumor xenografts in
athymic rats using GFP-labeled U87MG cells (n = 19).
Two weeks later, we injected either mCherry-AdFV-
hMSCs (n = 9) or mCherry-BM-hMSCs (n = 8) or saline
(n = 2) using different routes in separate rats, i.e., the
femoral vein, the common carotid artery, and the com-
mon carotid artery after ligation of the external carotid
artery (Fig. 3a). The xenografts were assessed by con-
focal microscopy from 1 h to 3 days after hMSC injec-
tion. Results showed that systemically injected hMSCs
are able to home to GBM parenchyma through the
tumor vasculature (Fig. 3b–e). This process takes place
as early as 1 h after injection and occurs mostly at the
tumor periphery, where angiogenesis is highly remark-
able (Fig. 3c). Strikingly, hMSCs were able to cross the
vessel wall only in regions where the architecture of the
brain vascularity was disrupted, as demonstrated by
immunofluorescence with markers for glial and endo-
thelial cells, and for the BBB (Fig. 3d). In regions where
the brain vessels maintained their normal architecture,
extravasation of hMSCs did not occur. Overall, the effi-
ciency of hMSCs homing to tumor xenografts was low
and related both to the route of cell injection and to
the source from which the hMSCs were derived. After
injection into the femoral vein, about 0.02% of Ad-hMSCs
engrafted at the site of the brain tumor. Conversely, injec-
tion of BM-hMSCs into the common carotid artery homo-
laterally to the tumor yielded an engraftment rate of 0.1%,
which increased to 0.5% by selectively injecting into the in-
ternal carotid artery. Interestingly, the amount of hMSCs
that were found in the lung, which works as a filter organ
for circulating hMSCs, decreased from 1 h to 24 h after
systemic injection, whereas the number of hMSCs homing
to the brain xenograft increased over the same time
frame, suggesting their ability to mobilize to sites of
vascularized tumor tissue (Additional file 3: Figure S3).
Systemically injected PTX-loaded Ad-hMSCs main-
tained their ability to home to the brain tumor and
induced cytotoxic damage to the surrounding tumor
cells (Fig. 3f ).
Of note, there was no mortality/morbidity related to
the injection of hMSCs, both after intravenous or intra-
arterial administration. On histological examination of
the lungs there were no findings suggesting pulmonary
embolism.
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Discussion
MSCs have gained considerable attention as a valuable
tool for cell therapy due to their intrinsic peculiarities;
first of all, their innate tropism for sites of injury, either
of inflammatory or neoplastic nature. MSCs are taken
into consideration as potential antitumor cells as well as
vehicles for gene therapy or for drug delivery. However,
the key issue of the effect the MSCs may exert on tumor
growth is still unclear. MSCs can indeed recruit more
immune cells into the tumor microenvironment, in-
crease the proportion of cancer stem cells, and promote
tumor angiogenesis, further supporting tumor progres-
sion. On the other hand, as plasticity is a fundamental
feature of MSCs, they can also inhibit tumor develop-
ment by activating different signaling pathways, eventu-
ally resulting in an inhibitory effect on tumor growth.
Such a dual role of MSCs on cancer biology has been
widely addressed in literature [29], where both protu-
morigenic [30, 31] and counter-tumorigenic effects are
reported [9–16, 32]. These discrepancies might depend
on a wide range of variables, including differences in
experimental settings, heterogeneity of MSCs, dose or
timing of MSC injection, and animal host or tumor
models. For instance, the dose of MSCs delivered is a
critical factor influencing tumor growth [33]. The timing
at which MSCs are inoculated into the tumor environ-
ment is another important issue. The presence of MSCs
during tumor development, as in the case of co-injection
of tumor cells and MSCs, undoubtedly influences the
tumor environment interfering with processes such as
angiogenesis and inflammation, which have a strong im-
pact on tumor growth. Interestingly, an opposite effect of
hMSC transplantation in a 4 T1 breast adenocarcinoma
model has been reported [34]. In this study, injection of
hMSCs derived from a single donor and grown in vitro
under the same conditions in animals with the same
disease resulted in a tumor-inhibiting or tumor-promoting
effect depending on the experimental protocol applied (co-
injection of hMSCs and tumor cells or injection of hMSCs
in tumor-bearing mice). Finally, MSCs may impact on the
immunosuppressive mechanisms in experimental mice
models. In the central nervous system (CNS) of experi-
mental autoimmune encephalomyelitis mice treated
with MSCs, a significant reduction of inflammation has
been reported, with a potent immunomodulatory effect
able to reduce neuroinflammation [35].
Opposite effects in in-vitro versus in-vivo models have
also been reported [36]. Moreover, the dichotomous
effect of MSCs has also been described in tumor angio-
genesis [16, 37–43]. The secretome of MSCs contains a
plethora of angiogenic mediators [44], whose ultimate
effect on tumor angiogenesis likely depends on the inter-
action between MSCs and the tumor microenvironment.
We previously demonstrated that murine BM-MSCs
are able to inhibit tumor growth in subcutaneous grafts
of U87MG cells, and that this effect is enhanced by loading
the MSCs with PTX [26]. The effects exerted by PTX treat-
ment on MSCs, both in terms of cell proliferation and
differentiation ability, have been addressed by several recent
papers. Ad-MSCs exposed to PTX lose their multipotent
differentiation capability both in in-vitro human Ad-MSC
populations and ex-vivo in rat Ad-MSC populations [45].
When PTX-treated hMSCs are induced to undergo adipo-
genesis they exhibit a 40% reduction in lipid accumulation
and adopt fibroblast-like characteristics, including up-
regulation of fibroblast markers and reduction of stemness
markers [46]. Similarly, PTX treatment strongly impairs
differentiation of AD-hMSCs towards the adipogenic,
osteogenic, and endothelial phenotypes [47].
We also showed that orthotopically injected murine BM-
MSCs loaded with PTX migrate towards U87MG brain xe-
nografts and induce cytotoxic damage in the tumor cells
[17]. One point we addressed here was using Ad-hMSCs in
orthotopic GBM models. The adipose tissue is less invasive
and less expensive than BM as a source of hMSCs. In
addition, Ad-hMSCs remain free of oncogenic transform-
ation for at least 8 months after injection in immunocom-
promised mice, demonstrating more oncogenic resistance
than BM-MSCs [48].
There are several strengths in the methods of the present
study. One concerns the use of hMSCs that constitutively
express the fluorescent mCherry protein. Although packing
of the mCherry protein in the cytoplasm may alter vitality
and/or motility of hMSCs, constitutive labeling of hMSCs
avoids the risk of false-positive results due to spurious
labeling which are inherent with the use of cell tracers
[49]. Another relevant aspect of our methods is the
intratumoral injection of hMSCs in the GSC xenograft,
(See figure on previous page.)
Fig. 2 Intratumoral injections of hMSCs in orthotopic xenografts of glioma stem-like cells (GSCs). a Schematic drawing of the intratumoral injection of
m-Cherry adipose-derived human mesenchymal stem/stromal cells (Ad-hMSCs) (red) in athymic rats with established brain xenografts of patient-derived
GSC1 tumor cells (green). b Low-power fluorescence microphotograph of a coronal section of rat brain through the tumor epicentre showing the injection
sites of Ad-hMSCs (arrow). Scale bar= 500 μm. c Microphtograph of GSC1 xenograft immunostained with anti-Iba1 (white staining) showing an area
injected with Ad-hMSCs with depletion of tumor cells and microglial reaction. Scale bar= 75 μm. d Bar graph showing the mean density of GSC1 tumor
cells in regions injected with Ad-hMSCs (grey bar) and in saline-injected region of control tumors (black bar; ***p< 0.0001). e Detail of interaction between
unloaded Ad-hMSCs and GSC1 tumor cells. Scale bar= 25 μm. f Detail of PTX-loaded Ad-hMSCs lying adjacent to a multinucleated GSC1 tumor cell (yellow
arrow). Scale bar= 25 μm. g–i Microphotographs showing cell proliferation, as assessed by Ki67 labeling, in GSC1 xenografts injected with g unloaded
Ad-hMSCs, h with PTX-loaded Ad-hMSCs, and i with saline. The arrows point out proliferating tumor cells. Scale bars= 75 μm
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an experimental condition where the therapeutic poten-
tial of hMSCs is tested against the radiochemoresistant
tumor cell population. Finally, planning different routes
for systemic administration provided valuable informa-
tion on homing efficiency of hMSCs to brain tumors.
Results from intracerebral injections in U87MG
xenografts showed that the Ad-hMSCs are able to
migrate through the brain and to colonize the tumor,
eventually leading to a significant extension of survival
that was associated with reduction of cell proliferation
and neo-vessel formation.
Although an anti-angiogenic effect of hMSCs has previ-
ously been reported in different tumor models [16, 37, 39],
the effect of Ad-hMSCs on microvessel density in our
U87MG xenografts was so striking as to deserve further
investigation. Current hypotheses that have been postu-
lated to explain the inhibition of tumor angiogenesis by
hMSCs include promotion of endothelial cell apoptosis
[50], modulation of the VE-cadherin/beta-catenin pathway
[39, 40], and suppression of vascular endothelial growth
factor (VEGF) expression [43]. In a glioma model, MSCs
have been demonstrated to exert anti-angiogenic activity
through downregulation of the platelet derived growth
factor (PDGF)-PDGFR axis, which is known to play a
key role in glioma angiogenesis [38].
The rationale for using GSCs in our study stems
from the notion that these cells give rise to tumor xe-
nografts closely mimicking the histological features of
human GBM and that they are responsible for therapy
resistance and recurrence, whereas the serum-
cultured GBM cells, such as the U87MG line, may be
assimilated to the tumor bulk. One major result of our
study is that the inhibitory action of hMSCs is exerted
both on the proliferating cells of the tumor bulk and
on the population of cancer stem cells (CSCs) respon-
sible for relapse and therapy resistance. A recent study
produced similar results, demonstrating that Ad-
hMSCs target brain tumor-initiating cells isolated
from the medulloblastoma, atypical teratoid/rhabdoid
tumors, and GBM [51]. Moreover, Ad-hMSCs engi-
neered to produce BMP4 effectively target CSC-
derived tumors in a rat model, resulting in extended
animal survival [52].
Unexpectedly, PTX loading of hMSCs did not substan-
tially affect the growth of U87MG xenografts. We noted
only a modest increase in the median survival in U87MG
xenografts (3/21 days, 17%) and some reduction of cell
proliferation in GSC1 xenografts (10.75 vs 14.35%, –25%),
both of which were not significant on statistical analysis.
In spite of the detection of PTX-induced cytotoxicity both
in U87MG and in GSC1 xenografts, overall tumor growth
was not significantly inhibited by the PTX-loaded Ad-
hMSCs compared with the unloaded Ad-hMSCs. One
explanation may be that PTX, although providing the
Ad-hMSCs with a powerful cytotoxic agent against the
tumor cells, may alter synthesis and/or secretion of those
factors involved in the antitumor action of Ad-hMSCs.
Alternatively, the brain region surrounding PTX-loaded
Ad-hMSCs where the released drug reaches cytotoxic levels
may be too small to affect the overall tumor growth. Actu-
ally, multinucleated tumor cells were mainly found within a
radius of 50 μm around the PTX-loaded hMSCs and
their number did not exceed five tumor cells per single
Ad-hMSC.
Another key aspect of our study concerns the potential
of using systemically administered hMSCs for tumor
therapy. This issue has recently been addressed by other
groups with encouraging results; however, some crucial
points, such as hMSCs crossing the brain endothelium
and drug-loaded hMSCs homing to the tumor, have not
been investigated [53, 54]. We here demonstrate that
hMSCs, even when loaded with PTX, are able to ex-
travasate and to localize in the brain tumor. Importantly,
this process takes place only where the BBB is disrupted,
whereas in regions where the brain vessels maintained
their normal architecture extravasation of hMSCs did
not occur. Although our data provide evidence that hMSCs
can be systemically administered as an innovative thera-
peutic option for GBM, the low homing efficiency of these
cells to brain xenografts may limit the feasibility of this
approach. Low homing efficiency of hMSCs in tumors
has also been reported by other researchers, who attempted
to increase homing by modulating the expression of surface
ligands that bind to intercellular adhesion molecules or by
preconditioning in vitro the hMSCs with GBM conditioned
medium and with matrix proteins [53, 55]. For example,
(See figure on previous page.)
Fig. 3 Systemic injection of hMSCs in established orthotopic xenografts of U87MG cells. a Schematic drawing of systemic injections of m-Cherry
hMSCs in athymic rats with established brain xenografts of U87MG cells. The hMSCs were injected either into the femoral vein (A), or into the
common carotid artery (B), or into the common carotid artery after ligation of the external carotid artery (C). Intra-arterial injections were performed on the
same side of the brain xenograft. b A microvessel lying in the brain hemisphere contralateral to the tumor that was immunostained with antibodies for
the endothelium (lectin, CD31), glial cells (GFAP), and blood-brain barrier (BBB) (SMI71). Scale bar= 10 μm. c,d Microphtographs of the brain-tumor interface
after intravenous injection of m-Cherry adipose-derived human mesenchymal stem/stromal cells (Ad-hMSCs). Intratumoral Ad-hMSCs were found only in
regions with absent perivascular astrocytic endings (c) and SMI71 immunostaining (d). Scale bar = 75 μm. e Microphtographs of tumor microvessels
obtained 1 h after intracarotid injection of m-Cherry BM-hMSCs showing transmigration through the vessel wall (center, anti-CD31 in purple; right, lectin
in purple). Scale bar = 25 μm. f Detail of a brain xenograft after intracarotid injection of paclitaxel (PTX)-loaded Ad-hMSCs. One Ad-hMSC is surrounded
by three multinucleated U87MG tumor cells (yellow arrows). Scale bar = 25 μm
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Smith et al. [53] reported that approximately 0.1% of
Ad-hMSCs injected via the intracardiac route homed to
U87MG brain xenografts and that less than one-half of
this amount reached the tumor from injections into the
tail vein. For both delivery routes, prime pretreatment
resulted in a sixfold increase in the engraftment rate. In
an ongoing study, we have found that preconditioning
hMSCs in vitro with tumor necrosis factor (TNF)-α in-
creases their adhesion to brain microvascular endothelial
cells, suggesting increased homing efficiency in vivo. To
enhance homing to GBM, however, we prefer to exploit
selective modalities for cell injection rather than ex vivo
manipulating the hMSCs, a procedure that is likely to
complicate the clinical use of these cells. Actually, select-
ive injection of hMSCs into the internal carotid artery
homolaterally to the brain xenograft was fivefold more
efficient than the intracardiac route and gave homing
rates quite similar to those achieved by the intracardiac
administration of primed hMSCs. From a clinical perspec-
tive, intra-arterial injections of hMSCs can be performed
in a highly selective fashion and, above all, can be safely
repeated as in the multistage embolization of cerebral
arteriovenous malformations.
Conclusion
The present work demonstrates that hMSCs are able to
migrate to and colonize GBM tumor xenografts when
injected directly into the brain or when systemically
administered. The interaction of hMSCs with the tumor
microenvironment results in a significant extension of
animal survival, reduced tumor volume, and impaired
cell proliferation and vascularization. Although further
studies are necessary to characterize this interaction at
the molecular level, our data support the possibility of
clinical use of hMSCs for treating malignant gliomas.
Additional files
Additional file 1: Figure S1. In vitro U87MG and GSC cell viability after
treatment with CM from PTX-loaded Ad-hMSCs. The kinetic of growth
inhibition induced by serial 1:2 dilutions of CM from PTX-loaded or unloaded
Ad-hMSCs on U87MG (left panel) or GSCs (right panel) is compared with the
growth inhibition exerted by direct PTX treatment (scaled 1:2
dilutions) on U87MG (left panel) and GSCs (right panel). Mean ± SD
are shown. (TIF 620 kb)
Additional file 2: Figure S2. In vitro coculture of U87MG and GSCs
with PTX-loaded or unloaded Ad-hMSCs. Coculturing tumor cells with
PTX-Ad-hMSCs, but not with Ad-hMSCs, results in a strong cytotoxic
effect evidenced by an increase in the number of altered spindles (white
arrowhead) and multinucleated tumor cells (yellow arrows) in both
U87MG (upper panel) and GSCs (lower panel) (a). Mono/multipolar spindles
significantly increase both in U87MG and in GSCs at 24 h of coculture with
PTX-AdMSCs (***p < 0.0001) (b). At 48 h of coculture, the PTX-Ad-hMSCs
induce a significant increase in the percentage of multinucleated cells of
both U87MG and GSCs (***p < 0.0001) (c). Scale bar = 25 μm. (TIF 9888 kb)
Additional file 3: Figure S3. Time course of hMSC homing to brain
U87MG xenografts and to lungs of matched rats. Fluorescence
microphotographs of GFP-expressing U87MG brain xenografts (left
panel) by 1 h and 24 h after injection of mCherry BM-hMSCs into
the common carotid artery with ligation of the external carotid
artery in athymic rats. The lungs of matched rats were also assessed by
fluorescence microscopy at the same time points (right panel). Scale bars =
80 μm for left pictures of panels; scale bars = 25 μm for right pictures of
panels. (TIF 9508 kb)
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